StockNews.com Begins Coverage on InspireMD (NYSE:NSPR)

Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report issued on Sunday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital began coverage on shares of InspireMD in a report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target on the stock.

InspireMD Stock Performance

NYSE:NSPR opened at $3.00 on Friday. The company’s 50-day simple moving average is $2.83 and its 200-day simple moving average is $2.76. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.80. The stock has a market capitalization of $78.25 million, a P/E ratio of -4.00 and a beta of 1.00.

Hedge Funds Weigh In On InspireMD

Hedge funds have recently modified their holdings of the stock. Affiance Financial LLC grew its position in InspireMD by 2.9% during the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of InspireMD during the fourth quarter worth $27,000. Legato Capital Management LLC purchased a new stake in shares of InspireMD during the fourth quarter valued at $47,000. Schonfeld Strategic Advisors LLC increased its position in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after acquiring an additional 18,233 shares during the period. Finally, Northern Trust Corp increased its position in shares of InspireMD by 103.7% in the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after acquiring an additional 24,452 shares during the period. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.